PLEASANTON, Calif., Nov. 29, 2017 -- Title21 Health Solutions, “Title21,” an innovator of integrated enterprise software for cell therapy and blood and marrow transplant programs supporting high-quality and world-class patient care announces its service to manage compliance of ISBT 128 labeling standards. With Title21 Compliance Care™ for ISBT 128 labeling, cell therapy facilities can rely on Title21 to update the ISBT 128 codes for their transplant program.
This add-on service is an extension of its current ISBT 128 Label Printing & Scanning Solution. ISBT 128 labels can be seamlessly printed and scanned throughout collections and cell manufacturing directly from Title21 to eliminate double-data entry and streamline product labeling and tracking activities. Title21 Compliance Care™ alleviates the burden of utilizing internal resources to maintain ICCBBA technical updates and ensures ongoing compliance and longevity of the program.
“Our goal is to deliver solutions that make it easier for cell therapy and BMT teams to deliver the highest quality of care to each patient,” stated Kent Kirimli, Chief Architect. “An important aspect of this is ensuring the technology implemented to support critical operations has the longevity and agility to adapt as things change without disrupting workflow. We identified that a fully-managed ISBT 128 Compliance Solution is an opportunity to further support the compliance, efficiency and patient safety of cell therapy and BMT programs.”
Title21’s ISBT 128 Label Printing & Scanning Solution is a part of a comprehensive platform to automate data management activities in regenerative medicine, cell and gene therapy programs. Title21’s integrated and modular platform offers solutions including Clinical Case Management, Collections, Laboratory Processing, Supplies & Equipment Management, Product Inventory Management, Chain of Custody, Batch Record and Product Release Review. The system natively integrates with Title21’s Enterprise Quality Management Software (EQMS) for consolidated electronic management of quality processes such as Document Control, Change Management, Training & Competency Management, Deviation Management, Corrective & Preventive Action (CAPA), Audit Management and Equipment Maintenance.
To learn more about Title21's solutions for ISBT 128 Labeling and Title21 Compliance Care, visit www.title21.com/isbt-128-labeling-software.
About Title21 Health Solutions
Title21 Health Solutions delivers easy-to-use, flexible and integrated technology to support health sciences organizations to gain efficiencies, improve compliance and ensure quality. Title21’s product line includes Enterprise Quality Management Solutions and an integrated, comprehensive Cellular Therapy Software. Learn more about Title21 Health Solutions at www.Title21.com.
Contact: Haley Roebuck Associate Marketing Manager 925-484-2121 [email protected]


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Instagram Outage Disrupts Thousands of U.S. Users
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 



